| Dr Peter Elliot Goldstein, MD | |
|
2925 West Ave, San Antonio, TX 78201-2243 | |
| (210) 761-3393 | |
| (210) 761-3397 |
| Full Name | Dr Peter Elliot Goldstein |
|---|---|
| Gender | Male |
| Speciality | Family Medicine |
| Location | 2925 West Ave, San Antonio, Texas |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154567980 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 180414 (New York) | Secondary |
| 207Q00000X | Family Medicine | N3677 (Texas) | Primary |
| Entity Name | Fisher County Hospital District |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104808112 PECOS PAC ID: 2163311465 Enrollment ID: O20040315000096 |
News Archive
Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management, announced today that Lysteda(TM) (tranexamic acid) oral tablets has received U.S. Food and Drug Administration (FDA) approval for treatment of women suffering from cyclic heavy menstrual bleeding (HMB), also known as menorrhagia.
Symphogen, a private biopharmaceutical company developing superior antibody therapeutics, said the company had been granted a US patent for Sym004 as well as other antibody compositions containing at least two distinct anti-EGFR antibodies having certain binding characteristics.
Gemalto, the world leader in digital security, today announced that Bulgaria has started deploying its smart cards to secure access to personal health records for the country's military personnel and their family.
All persons taking strontium supplements are warned that significant risks have been identified. Strontium drugs are not approved for treatment of osteoporosis in the United States. Now, the Risk Assessment Committee of the European Medicines Agency recommended that strontium should no longer be used to treat osteoporosis in Europe. The drugs Protelos/Osseor were specifically named as brand names for strontium ranelate.
› Verified 7 days ago
| Entity Name | Health And Human Services Commission |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356414692 PECOS PAC ID: 2163795824 Enrollment ID: O20170908001058 |
News Archive
Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management, announced today that Lysteda(TM) (tranexamic acid) oral tablets has received U.S. Food and Drug Administration (FDA) approval for treatment of women suffering from cyclic heavy menstrual bleeding (HMB), also known as menorrhagia.
Symphogen, a private biopharmaceutical company developing superior antibody therapeutics, said the company had been granted a US patent for Sym004 as well as other antibody compositions containing at least two distinct anti-EGFR antibodies having certain binding characteristics.
Gemalto, the world leader in digital security, today announced that Bulgaria has started deploying its smart cards to secure access to personal health records for the country's military personnel and their family.
All persons taking strontium supplements are warned that significant risks have been identified. Strontium drugs are not approved for treatment of osteoporosis in the United States. Now, the Risk Assessment Committee of the European Medicines Agency recommended that strontium should no longer be used to treat osteoporosis in Europe. The drugs Protelos/Osseor were specifically named as brand names for strontium ranelate.
› Verified 7 days ago
| Entity Name | Open Arms Healthcare Of Texas Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639656325 PECOS PAC ID: 9436400579 Enrollment ID: O20180928000718 |
News Archive
Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management, announced today that Lysteda(TM) (tranexamic acid) oral tablets has received U.S. Food and Drug Administration (FDA) approval for treatment of women suffering from cyclic heavy menstrual bleeding (HMB), also known as menorrhagia.
Symphogen, a private biopharmaceutical company developing superior antibody therapeutics, said the company had been granted a US patent for Sym004 as well as other antibody compositions containing at least two distinct anti-EGFR antibodies having certain binding characteristics.
Gemalto, the world leader in digital security, today announced that Bulgaria has started deploying its smart cards to secure access to personal health records for the country's military personnel and their family.
All persons taking strontium supplements are warned that significant risks have been identified. Strontium drugs are not approved for treatment of osteoporosis in the United States. Now, the Risk Assessment Committee of the European Medicines Agency recommended that strontium should no longer be used to treat osteoporosis in Europe. The drugs Protelos/Osseor were specifically named as brand names for strontium ranelate.
› Verified 7 days ago
| Entity Name | Austin City Family Practice Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770241192 PECOS PAC ID: 8527444090 Enrollment ID: O20221006001777 |
News Archive
Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management, announced today that Lysteda(TM) (tranexamic acid) oral tablets has received U.S. Food and Drug Administration (FDA) approval for treatment of women suffering from cyclic heavy menstrual bleeding (HMB), also known as menorrhagia.
Symphogen, a private biopharmaceutical company developing superior antibody therapeutics, said the company had been granted a US patent for Sym004 as well as other antibody compositions containing at least two distinct anti-EGFR antibodies having certain binding characteristics.
Gemalto, the world leader in digital security, today announced that Bulgaria has started deploying its smart cards to secure access to personal health records for the country's military personnel and their family.
All persons taking strontium supplements are warned that significant risks have been identified. Strontium drugs are not approved for treatment of osteoporosis in the United States. Now, the Risk Assessment Committee of the European Medicines Agency recommended that strontium should no longer be used to treat osteoporosis in Europe. The drugs Protelos/Osseor were specifically named as brand names for strontium ranelate.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Peter Elliot Goldstein, MD 2925 West Ave, San Antonio, TX 78201-2243 Ph: (210) 761-3393 | Dr Peter Elliot Goldstein, MD 2925 West Ave, San Antonio, TX 78201-2243 Ph: (210) 761-3393 |
News Archive
Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management, announced today that Lysteda(TM) (tranexamic acid) oral tablets has received U.S. Food and Drug Administration (FDA) approval for treatment of women suffering from cyclic heavy menstrual bleeding (HMB), also known as menorrhagia.
Symphogen, a private biopharmaceutical company developing superior antibody therapeutics, said the company had been granted a US patent for Sym004 as well as other antibody compositions containing at least two distinct anti-EGFR antibodies having certain binding characteristics.
Gemalto, the world leader in digital security, today announced that Bulgaria has started deploying its smart cards to secure access to personal health records for the country's military personnel and their family.
All persons taking strontium supplements are warned that significant risks have been identified. Strontium drugs are not approved for treatment of osteoporosis in the United States. Now, the Risk Assessment Committee of the European Medicines Agency recommended that strontium should no longer be used to treat osteoporosis in Europe. The drugs Protelos/Osseor were specifically named as brand names for strontium ranelate.
› Verified 7 days ago
Dr. Obinna C. Uzowulu, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 22250 Bulverde Rd, Suite 111, San Antonio, TX 78261 Phone: 210-899-4490 Fax: 210-592-8195 | |
Dr. Salima Jaffer, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 22800 Bulverde Rd Apt 2202, San Antonio, TX 78261 Phone: 210-878-4033 | |
David A. Ramos, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3110 Nogalitos, Suite 105, San Antonio, TX 78225 Phone: 210-533-0257 Fax: 210-534-0890 | |
Patricia May B. Lacsina, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 903 W Martin St, San Antonio, TX 78207 Phone: 210-358-3441 Fax: 210-358-5944 | |
Adriana S Sanchez, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 8300 Floyd Curl Dr, San Antonio, TX 78229 Phone: 210-450-9000 | |
Dr. Aneela N. Hussain, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 4610 E Southcross Blvd, San Antonio, TX 78222 Phone: 210-648-1491 | |
Javier C Bocanegra, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1616 Callaghan Rd, San Antonio, TX 78228 Phone: 210-435-1218 Fax: 210-435-3162 |